Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of IMAB
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Weaker technical forecast for I-Mab as stock downgraded to Strong Sell Candidate.
(Updated on Jul 02, 2024)

Sell candidate since Jun 13, 2024 Loss -15.05% PDF

The I-Mab stock price fell by -2.47% on the last day (Tuesday, 2nd Jul 2024) from $1.62 to $1.58. It has now fallen 5 days in a row. During the last trading day the stock fluctuated 3.82% from a day low at $1.57 to a day high of $1.63. The price has fallen in 8 of the last 10 days and is down by -13.19% for this period. Volume has increased on the last day by 43 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 146 thousand shares were bought and sold for approximately $230.84 thousand.

The stock lies in the lower of a wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.55 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -4.58% during the next 3 months and, with a 90% probability hold a price between $1.48 and $1.79 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

IMAB Signals & Forecast

There are few to no technical positive signals at the moment. The I-Mab stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $1.67 and $1.76. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, June 05, 2024, and so far it has fallen -16.84%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). I-Mab gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss for I-Mab stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.0600 between high and low, or 3.82%. For the last week, the stock has had daily average volatility of 5.58%.

I-Mab is oversold on RSI14 (13). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (IMAB) For The Upcoming Trading Day Of Wednesday 3rd

For the upcoming trading day on Wednesday, 3rd we expect I-Mab to open at $1.59, and during the day (based on 14 day Average True Range), to move between $1.50 and $1.66, which gives a possible trading interval of +/-$0.0782 (+/-4.95%) up or down from last closing price. If I-Mab takes out the full calculated possible swing range there will be an estimated 9.90% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $1.80, some $0.220 (13.92%) from the current price of $1.58, our system finds the risk reward not very attractive.

Is I-Mab stock A Buy?

I-Mab holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -5.073 Strong Sell Candidate Downgraded

Predicted Opening Price for I-Mab of Wednesday, July 3, 2024

Fair opening price July 3, 2024 Current price
$1.59 ( 0.84%) $1.58

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for IMAB

Fibonacci Support & Resistance Levels

Level Price
R3 1.65 4.64%
R2 1.63 3.19%
R1 1.62 2.29%
Price 1.58
S1 1.57 -0.607%
S2 1.56 -1.50%
S3 1.53 -2.95%

Accumulated Volume Support & Resistance Levels

Level Price
R3 1.88 18.99%
R2 1.81 14.56%
R1 1.80 13.92%
Price 1.58
S1 0 -
S2 0 -
S3 0 -

FAQ

What is the symbol for I-Mab Stock and on which exchange is it traded?
The symbol for I-Mab is IMAB and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell I-Mab Stock?
I-Mab holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

How to buy I-Mab Stock?
I-Mab Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy I-Mab Stock.

What's the current price of I-Mab Stock?
As of the end of day on the Jul 02, 2024, the price of an I-Mab (IMAB) share was $1.58.

What is the 52-week high and low for I-Mab Stock?
The 52-week high for I-Mab Stock is $3.17 and the 52-week low is $1.16.

What is the market capitalization of I-Mab Stock?
As of the Jul 02, 2024, the market capitalization of I-Mab is 124.778M.

When is the next earnings date for I-Mab?
The upcoming earnings date for I-Mab is Aug 15, 2024.
Click to get the best stock tips daily for free!

About I-Mab

I-Mab I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Pha... IMAB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT